WHO最新建議!可採用HPV mRNA檢測做為子宮頸癌第一線篩檢工具

保佳生技, HPV mRNA 檢測, WHO建議子宮頸癌第一線篩檢工具



2021年12月21日WHO更新第二版子宮頸癌防治建議,其中三項關於HPV mRNA的建議值得注意:

(1) 可採用HPV mRNA做為子宮頸癌第一線篩檢工具;

保佳生技, HPV mRNA 檢測, WHO建議子宮頸癌第一線篩檢工具

(2) 此外,HPV mRNA篩檢結果也可以與臨床決策銜接,例如HPV mRNA篩檢結果接續治療方式或以醋酸塗抹、陰道鏡、細胞學進行分類。

保佳生技, HPV mRNA 檢測, WHO建議子宮頸癌第一線篩檢工具

(3) 新版WHO guideline中並指出,Hologic Aptima mRNA檢測是目前唯一具有足夠研究資料佐証的HPV mRNA檢測方法,以real-time TMA的自動化儀器,大量檢測HPV E6/E7致癌基因 mRNA,並表現出與HPV DNA test相同的靈敏度,但對CIN2+的病灶表現出更高的特異性,顯示Hologic Aptima mRNA檢測可以偵測HPV存出更需要密切追蹤的病患。

“At present there is only one technology commercially available and widely documented in the literature, called the AptimaTM mRNA assay, that can qualitatively detect the expression of HPV E6 and E7 mRNA from all 14 high-risk types of HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) through real-time amplification. This system can carry out up to 250 tests in approximately five hours. There are two other assays that target fewer oncogenic types, but information and use remains limited at this time.”

參考資料: https://www.who.int/publications/i/item/9789240040434

欲了解詳細資訊,歡迎聯繫產品專員 陸詩羽,連絡電話: 02-2246-7799 #805

Scroll to Top